Pathos AI
IL - ChicagoBiotechnology
Focus: Pathos AI is an early-stage oncology-focused biotech company founded in 2022 that specializes in in-licensing clinical-stage drugs. The company is pre-revenue and operates at Series A stage with a minimal disclosed footprint.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
SERIES A
Open Jobs
0
About Pathos AI
AI assessmentNot HiringNo open roles listed right now. Follow Pathos AI to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_1_2
Clinical Trials (1)
NCT06785636Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Phase 1/2Help build intelligence for Pathos AI
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.